Sebastiano Filetti
Annals of Oncology · 2010–2019
A researcher in the Science corpus: 3 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from Sebastiano Filetti's perspective
Ordered by how strongly the researchers Sebastiano Filetti trusts endorse each paper. Same corpus, a different order for every researcher.
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (European Journal of Endocrinology)
- Extent of Surgery Affects Survival for Papillary Thyroid Cancer (Annals of Surgery)
- Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (Journal of Clinical Endocrinology and Metabolism)
- Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial (The Lancet)
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (New England Journal of Medicine)
- Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide (L Endocrinologo)
- Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma (JAMA Oncology)
- Guidelines for radioiodine therapy of differentiated thyroid cancer (European Journal of Nuclear Medicine and Molecular Imaging)
- Strategies of radioiodine ablation in patients with low-risk thyroid cancer. (New England Journal of Medicine)
Their papers
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) — 815 citations
- The Diagnosis and Management of Thyroid Nodules: A Review (2018) — 715 citations
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (2010) — 610 citations